Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(-2031³â) - ÀûÀÀÁõº°, ¾à¹° À¯Çüº°, Åõ¿© ¸ðµåº°, À¯Åë ä³Îº°, Áö¿ªº°
Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
»óǰÄÚµå : 1410592
¸®¼­Ä¡»ç : Fairfield Market Research
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 170 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 6,977,000
Unprintable PDF & Excel (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 11,866,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®´Â Copy & Paste °¡´ÉÇÏÁö¸¸, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 10,600 £Ü 14,807,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ëÀÚ¼ö´Â 5¸í ÀÌ»óÀ̸ç Á¦ÇÑÀº ¾ø½À´Ï´Ù. Copy & Paste ¹× Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áö±Ý Àü ¼¼°èÀûÀ¸·Î À¯ÇàÇϰí ÀÖ´Â ºñ¸¸Àº ´Ù³¶¼º³­¼ÒÁõÈıº, °©»ó¼±±â´ÉÀúÇÏÁõ°ú °°Àº ÈçÇÑ Áúȯ»Ó¸¸ ¾Æ´Ï¶ó ½Ã»óÇϺÎÀå¾Ö, Äí½ÌÁõÈıº°ú °°Àº Èñ±ÍÁúȯÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ³»ºÐºñÁúȯ°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

ºñ¸¸ ¹ß»ýÀÇ ±âº» ¸ÞÄ¿´ÏÁòÀº ƯÁ¤ ³»ºÐºñÁúȯ¿¡ µû¶ó ´Ù¸¨´Ï´Ù. µå¹® ³»ºÐºñÁúȯÀÇ °æ¿ì, ¼ºÀå È£¸£¸ó ¹× °©»ó¼± ±â´É°úÀÇ »óÈ£ÀÛ¿ëÀÌ ¸Å¿ì Áß¿äÇϸç, ¸¹Àº °æ¿ì Áö¹æ »ý¼º ¹× Áö¹æ¼¼Æ÷ ºÐÈ­ Áõ°¡¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

Àü ¼¼°è ¿¬±¸ÀÚµéÀº Èñ±Í ³»ºÐºñÁúȯÀÇ Ä¡·á Àü·« Æò°¡¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖÀ¸¸ç, ƯÈ÷ °úüÁß È¯ÀÚ¿¡°Ô ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ´ºÄ³½½ ´ëÇÐÀÇ °úÇÐÀÚµéÀº ´Ù¾çÇÑ º´ÀÎ ¿äÀÎÀ» °í·ÁÇϸ鼭 ºñ¸¸ ¹ßº´ÀÇ ÀÚ¿¬»ç¸¦ ¿­½ÉÈ÷ Æò°¡Çϰí ÀÖ½À´Ï´Ù.

Á¾ÇÕÀûÀÎ Æò°¡´Â ¾ÆÁ÷ ÀÌ·ç¾îÁöÁö ¾Ê¾ÒÁö¸¸, ¿¬±¸ÀÚµéÀº Æò°¡ °úÁ¤À» È®ÀåÇϰí ÀϹÝÀûÀÎ ³»ºÐºñÇÐÀû ¿øÀÎÀ» ¹èÁ¦Çϰí ÀûÀýÇÑ Ä¡·á¹ýÀ» ¼±ÅÃÇÒ ¼öÀÖ´Â ±æÀ» ¿­±â À§ÇØ ÀÓ»ó °Ë»ç¿Í ½Åü °Ë»ç¸¦ ½Ç½ÃÇϰí ÀÖ½À´Ï´Ù.

³»ºÐºñÁúȯÀÇ Èñ±Í¼ºÀ¸·Î ÀÎÇØ ¿¬±¸ÀÚ¿Í ÀÓ»óÀÇ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ÀÓ»ó½ÃÇèÀ» À§ÇØ ÃæºÐÇÑ È¯ÀÚ µ¥ÀÌÅ͸¦ ¼öÁýÇØ¾ß ÇÏ´Â °úÁ¦¸¦ ¾È°í ÀÖ½À´Ï´Ù. Endocrine Genomics Virtual Laboratory(endoVL)´Â ºÐ¼® µµ±¸¿Í ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ ¼¼Æ®¿¡ ´ëÇÑ ¾ÈÀüÇÑ ¿Â¶óÀÎ ¾×¼¼½º¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϰí Èñ±Í ³»ºÐºñÁúȯÀÇ Áø´Ü°ú Ä¡·á¸¦ ¹ßÀü½Ãų ¼ö ÀÖ´Â °øµ¿ ¿¬±¸¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

8,500°Ç ÀÌ»óÀÇ ºÎ½ÅÁ¾¾ç ȯÀÚ°¡ µî·ÏµÈ endoVLÀº ¿¬±¸ÀÚµéÀÌ ´ë±Ô¸ð ÄÚȣƮ¸¦ Ȱ¿ëÇÏ¿© Åë°èÀûÀ¸·Î À¯ÀǹÌÇÑ ºÐ¼®À» ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÇöÀç endoVL¿¡´Â 25°³ ÀÌ»óÀÇ ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̸ç, Àü ¼¼°è ¿¬±¸ ±×·ìÀÌ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °øµ¿ ¿¬±¸ ³ë·ÂÀº Àü ¼¼°è Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå¿¡¼­ »õ·Î¿î ¼ºÀå ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

Èñ±Í ³»ºÐºñÁúȯÀº Á¾Á¾ ´Ù±â°ü Áõ»óÀ» ³ªÅ¸³»¸ç, ¶Ñ·ÇÇÑ º´Å»ý¸®ÇÐÀû Àå¾Ö·Î ÀÎÇØ ´«¿¡ ¸ÕÀú ³ªÅ¸³ª´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Èñ±Í ³»ºÐºñÁúȯÀÇ ¾È°úÀû Áõ»óÀ» ÀνÄÇÏ´Â °ÍÀº ½Å¼ÓÇÑ Áø´Ü, Ä¡·á ¹× ½É°¢ÇÑ ÀÌȯÀ²°ú »ç¸Á·üÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

»ý¸í°øÇÐ ¹× Á¦¾à±â¾÷Àº ÀÇÇÐ ¿¬±¸ÀÚµé°ú ÇÔ²² Èñ±Í ³»ºÐºñÁúȯÀÇ ¾È°úÀû Áõ»ó ´ëÀÀ¿¡ ÁýÁßÇÏ¿© ÀÌ Áß¿äÇÑ ºÐ¾ßÀÇ Ä¡·á¹ý °³¹ß ¹× ±â¼ú Çõ½ÅÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

º» º¸°í¼­´Â ¼¼°è Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ÀûÀÀÁõº°, ¾à¹° Á¾·ùº°, Åõ¿© ¸ðµåº°, À¯Åë ä³Îº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ °æÀï µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ¼¼°èÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦4Àå ºÏ¹ÌÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦5Àå À¯·´ÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦7Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦8Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Èñ±Í ³»ºÐºñÁúȯ Ä¡·á ½ÃÀå Àü¸Á, 2018-2031³â

Á¦9Àå °æÀï »óȲ

Á¦10Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted by Fairfield Market Research.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

Drug Type

Mode of Administration

Distribution Channel

Region

Table of Contents

1. Executive Summary

2. Market Overview

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

9. Competitive Landscape

9.5.12.

10. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â